Antiparkinsonian Effect of Nutmeg Ethanolic Extract (Myristica fragrans Houtt.) in Haloperidol-induced Mice

Authors

DOI:

https://doi.org/10.12928/pharmaciana.v14i1.27705

Keywords:

Myristica fragrans, Antiparkinsonian, Cylinder test, Rotarod test

Abstract

Parkinson's disease is a chronic neurological illness that may be caused by a decrease in dopaminergic neurons in the brain. Myristicin, eugenol, and flavonoids, which are bioactive compounds in nutmeg (Myristica fragrans Houtt.), may be able to treat Parkinson's disease. The goal of this study was to find out the antiparkinsonian effect of nutmeg in haloperidol-induced Parkinson's disease mice. Induction with haloperidol was carried out intraperitoneally for 7 consecutive days. Treatment with nutmeg uses three different doses (5, 10, and 20 mg/kg) for 7 days orally. Behavioral testing is carried out using the Rotarod test and the cylinder test. The results showed that nutmeg at a dose of 20 mg/kg was able to show significant improvement (P < 0.05) in the motor condition of test animals induced by haloperidol.

References

Ay, M. et al. (2017) ‘Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson’s Disease’, Journal of Neurochemistry, 141(5), pp. 766–782. doi: 10.1111/jnc.14033.

Ball, N. et al. (2019) ‘Parkinson’s Disease and the Environment’, Frontiers in Neurology, 10. doi: 10.3389/fneur.2019.00218.

Erjavec, G. N. et al. (2022) ‘SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism’, Biomedicines, 10(3237), pp. 1–16.

Essam, R. M. and Kandil, E. A. (2023) ‘p-CREB and p-DARPP-32 orchestrating the modulatory role of cAMP/PKA signaling pathway enhanced by Roflumilast in rotenone-induced Parkinson’s disease in rats’, Chemico-Biological Interactions, 372, p. 110366. doi: 10.1016/j.cbi.2023.110366.

Grubor, M. et al. (2020) ‘Polymorphisms and Extrapyramidal Side E ff ects in Haloperidol-Treated Patients with Schizophrenia’, International Journal of Molecular Sciences, 21(2345), pp. 1–15.

Hanifah, A. and Tristantini, D. (2019) ‘Total phenolic, UPLC-QTOF-MS analysis and antidepressant-like effect in the mice forced swim test of Jamu Neuropathic Pain Reducer’, AIP Conference Proceedings, 2193(December). doi: 10.1063/1.5139347.

Harris, J. P. et al. (2020) ‘Emerging regenerative medicine and tissue engineering strategies for Parkinson’s disease’, Nature Partner Journals Parkinson’s Disease. Nature Research, pp. 1–14. doi: 10.1038/s41531-019-0105-5.

Hasanusi, I. N. et al. (2020) ‘Effects Of Ethanol Extract Of Nutmeg Seeds (Myristica fragrans Houtt) On Mice Anxiety’, Pattimura Medical Review, 2(1), pp. 36–46. Available at: https://ojs3.unpatti.ac.id/index.php/pameri/index.

Hayes, M. T. (2019) Parkinson’s Disease and Parkinsonism, American Journal of Medicine. Elsevier Inc. doi: 10.1016/j.amjmed.2019.03.001.

Jeong, S. et al. (2021) ‘Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson’s disease’, PLoS ONE, 16(3 March), pp. 1–13. doi: 10.1371/journal.pone.0247354.

Jiang, P.-E. et al. (2019) ‘Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson’s Disease Model’, Journal of Visualized Experiments, (143). doi: 10.3791/58653.

Jung, U. J. and Kim, S. R. (2018) ‘Beneficial Effects of Flavonoids Against Parkinson’s Disease’, Journal of Medicinal Food, 21(5), pp. 421–432. doi: 10.1089/jmf.2017.4078.

Kabra, A. et al. (2020) ‘Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson’s disease’, Journal of Ayurveda and Integrative Medicine, 11(4), pp. 448–454. doi: 10.1016/j.jaim.2020.06.007.

Kawano, M. et al. (2020) ‘Tannic acid acts as an agonist of the dopamine D2L receptor, regulates immune responses, and ameliorates experimentally induced colitis in mice’, Brain, Behavior, & Immunity - Health, 5(March), p. 100071. doi: 10.1016/j.bbih.2020.100071.

Khazdair, M. R., Kianmehr, M. and Anaeigoudari, A. (2020) ‘Effects of Medicinal Plants and Flavonoids on Parkinson’s Disease, a Review on Basic and Clinical Evidences’, Advanced Pharmaceutical Bulletin, 11(2), pp. 224–232. doi: 10.34172/apb.2021.026.

Leem, Y. H. et al. (2022) ‘Neurogenic effects of rotarod walking exercise in subventricular zone, subgranular zone, and substantia nigra in MPTP-induced Parkinson’s disease mice’, Scientific Reports, 12(1), pp. 1–16. doi: 10.1038/s41598-022-14823-5.

Magno, L. A. et al. (2019) ‘Cylinder Test to Assess Sensory-Motor Function in a Mouse Model of Parkinson’s Disease’, Bio-Protocol, 9(16), pp. 1–8. doi: 10.21769/bioprotoc.3337.

Maher, P. (2019) ‘The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases’, International journal of molecular sciences, 20(3056), pp. 1–9.

Malaiwong, N. et al. (2019) ‘Anti-Parkinson activity of bioactive substances extracted from Holothuria leucospilota’, Biomedicine & Pharmacotherapy, 109, pp. 1967–1977. doi: 10.1016/j.biopha.2018.11.063.

Noviyandri, P. R., Nurhadisah and Chismirina, S. (2021) ‘Effect of Nutmeg Flesh (Myristica fragrans Houtt) against Streptococcus mutans growth’, Journal of Syiah Kuala Dentistry Society, 5(1), pp. 42–46. doi: 10.24815/jds.v5i1.19682.

Saleem, U. et al. (2021) ‘Appraisal of anti-Parkinson activity of rhinacanthin-C in haloperidol-induced parkinsonism in mice: A mechanistic approach’, Journal of Food Biochemistry, 45(4), pp. 1–13. doi: 10.1111/jfbc.13677.

Seneme, E. F. et al. (2021) ‘Pharmacological and therapeutic potential of myristicin: A literature review’, Molecules, 26(19), pp. 1–15. doi: 10.3390/molecules26195914.

Shin, S. W. et al. (2019) ‘Antipsychotics for patients with pain’, The Korean Journal of Pain, 32(1), pp. 3–11. doi: 10.3344/kjp.2018.32.1.3.

Skinner, J. W., Christou, E. A. and Hass, C. J. (2019) ‘Lower Extremity Muscle Strength and Force Variability in Persons With Parkinson Disease’, Journal of Neurologic Physical Therapy, 43(1), pp. 56–62. doi: 10.1097/NPT.0000000000000244.

Weng, J. J. et al. (2019) ‘Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: A stage-1 open-label pilot study’, Neuropsychiatric Disease and Treatment, 15, pp. 2195–2203. doi: 10.2147/NDT.S205933.

Yulianita, Y., Effendi, E. M. and Firdayani, E. M. (2019) ‘Sedative Effect of Citronella (Cymbopogon nardus (L.) Rendle) Towards Male Mice (Mus musculus)’, Indonesian Journal of Pharmaceutical Science and Technology Journal Homepage, 1(1), pp. 16–23. Available at: http://jurnal.unpad.ac.id/ijpst/.

Downloads

Published

2024-03-29

Issue

Vol. 14 No. 1 (2024): Pharmaciana

Section

Pharmacology

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.